Coverage
-
July 31, 2018
A recipe related to Janssen Biotech Inc.'s blockbuster immunosuppressant Remicade was too obvious for any competitor to have legally infringed a patent on it, a Massachusetts federal judge ruled Tuesday, allowing Pfizer Inc. to rest easy about the validity of its new-to-market equivalent to treat arthritis and psoriasis among other common conditions.
6 other articles on this case.
View all »